Darunavir — Discount Pricing

Other medications in Infections

• Dicloxacillin
• Dolutegravir
• Doripenem
• Efavirenz
• Emtricitabine
• Entecavir
• Ertapenem
• Erythromycin

About Darunavir

Darunavir is a crucial medication in the fight against HIV-1, helping individuals manage their condition and improve their quality of life. At TheDrugClub, we understand the financial burden of such vital prescriptions. Our membership program is designed to help you access darunavir and other medications at a more affordable price, ensuring you can prioritize your health without compromise.

Darunavir, often recognized by its brand name Prezista, is a powerful antiretroviral medication prescribed for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. It is typically used in combination with other antiretroviral drugs as part of a comprehensive treatment regimen. For individuals living with HIV, adherence to prescribed medication is paramount for managing the virus, preventing its progression, and maintaining a healthy immune system.

How Darunavir Works

Darunavir belongs to a class of drugs called protease inhibitors (PIs). HIV, like other viruses, needs to replicate to survive and spread. The virus produces long protein chains that must be cut into smaller, functional pieces by an enzyme called protease. Darunavir works by blocking this essential HIV protease enzyme. By inhibiting protease, darunavir prevents the virus from maturing and assembling new infectious viral particles. This action significantly reduces the viral load (the amount of HIV in the blood) and helps to increase CD4 cell counts, strengthening the body's immune system and reducing the risk of opportunistic infections.

Typical Costs of Darunavir

As a highly effective and specialized medication, darunavir can be quite expensive. The list price for a month's supply can be substantial, often ranging into thousands of dollars, making it

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Darunavir is approved for (FDA label)

Darunavir tablets, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations (8.4) and Clinical Studies (14)] . Darunavir tablets are a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. Darunavir tablets must be co-administered with ritonavir (darunavir/ritonavir) and with other antiretroviral agents. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: March 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Darunavir (FDA label)

Darunavir Tablets 600 mg: Beige colored, oval-shaped, bi-convex, film-coated tablets, debossed with “M” on one side and “600” on other side. 800 mg: Brown colored, oval-shaped, bi-convex, film-coated tablets, debossed with “M” on one side and “800” on other side. Tablets: 600 mg and 800 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: e80e44f8-1987-4b78-a63d-a4e4d5122ddb. SPL document ID: 585d2da0-738a-48d3-8995-bdb8959a0193. Label effective date: March 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Darunavir (FDA label)

The following adverse reactions are discussed in other sections of labeling: Hepatotoxicity [see Warnings and Precautions (5.2 )] Severe Skin Reactions [see Warnings and Precautions (5.3 )] Diabetes Mellitus/Hyperglycemia [see Warnings and Precautions (5.6 )] Fat Redistribution [see Warnings and Precautions (5.7) ] Immune Reconstitution Syndrome [see Warnings and Precautions (5.8 )] Hemophilia [see Warnings and Precautions (5.9)] Due to the need for co-administration of darunavir with ritonavir, please refer to ritonavir prescribing information for ritonavir-associated adverse reactions.

Source: FDA prescribing information (DailyMed). Set ID: e80e44f8-1987-4b78-a63d-a4e4d5122ddb. SPL document ID: 585d2da0-738a-48d3-8995-bdb8959a0193. Label effective date: March 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Darunavir (FDA label)

Co-administration of darunavir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). Examples of these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below [see Drug Interactions (7.3 )] . Due to the need for co-administration of darunavir with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. • Alpha 1-adrenoreceptor antagonist: alfuzosin • Anti-gout: colchicine, in patients with renal and/or hepatic impairment • Antimycobacterial: rifampin • Antipsychotics: lurasidone, pimozide • Cardiac Disorders: dronedarone, ivabradine, ranolazine • Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine • Herbal product: St.

Source: FDA prescribing information (DailyMed). Set ID: e80e44f8-1987-4b78-a63d-a4e4d5122ddb. SPL document ID: 585d2da0-738a-48d3-8995-bdb8959a0193. Label effective date: March 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Darunavir (FDA label)

Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with darunavir/ritonavir. Monitor liver function before and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases. Post-marketing cases of liver injury, including some fatalities, have been reported. ( 5.2 ) Skin reactions ranging from mild to severe, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis, have been reported. Discontinue treatment if severe reaction develops. ( 5.3 ) Use with caution in patients with a known sulfonamide allergy. ( 5.4 ) Patients may develop new onset diabetes mellitus or hyperglycemia.

Source: FDA prescribing information (DailyMed). Set ID: e80e44f8-1987-4b78-a63d-a4e4d5122ddb. SPL document ID: 585d2da0-738a-48d3-8995-bdb8959a0193. Label effective date: March 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Darunavir (FDA label)

Co-administration of darunavir/ritonavir with other drugs can alter the concentrations of other drugs and other drugs may alter the concentrations of darunavir. The potential drug-drug interactions must be considered prior to and during therapy. ( 4 , 5.5 , 7 , 12.3 ) 7.1 Potential for darunavir/ritonavir to Affect Other Drugs Darunavir co-administered with ritonavir is an inhibitor of CYP3A, CYP2D6, and P-gp. Co-administration of darunavir and ritonavir with drugs that are primarily metabolized by CYP3A and CYP2D6 or are transported by P-gp may result in increased plasma concentrations of such drugs, which could increase or prolong their therapeutic effect and adverse events.

Source: FDA prescribing information (DailyMed). Set ID: e80e44f8-1987-4b78-a63d-a4e4d5122ddb. SPL document ID: 585d2da0-738a-48d3-8995-bdb8959a0193. Label effective date: March 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.